CD4 and AIDS: Higher CD4+ T lymphocytes before initiating HAART has been demonstrated to predict better prognosis, and some reports emphasized that patients suffering from pre-treatment immunodeficiency or AIDS-defining conditions may have greater risks of morbidity and mortality both before and during the initial months of HAART [18].